Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 1, keine Gesamtzahl für „govitecan“
Suchtreffer
Begriffe & Kennungen
Trodelvy · 4.5 · Concomitant administration of sacituzumab govitecan with inhibitors of UGT1A1 may increase the incidence of ad
Eintrag öffnenTrodelvy · 4.8 · Adverse reactions observed in clinical studies of sacituzumab govitecan as monotherapy or in combination with
Eintrag öffnenTrodelvy · 4.8 · Adverse reactions occurring in patients treated with sacituzumab govitecan in combination with pembrolizumab w
Eintrag öffnenTrodelvy · 4.8 · Diarrhoea occurred in 59.9% of patients treated with sacituzumab govitecan. Grade 3 events occurred in 10.0% o
Eintrag öffnenTrodelvy · 4.8 · Febrile neutropenia occurred in 5.6% of patients treated with sacituzumab govitecan. Febrile neutropenia was t
Eintrag öffnenTrodelvy · 4.8 · Immunogenicity Across clinical studies in patients treated with sacituzumab govitecan, 13 (1.2%) of 1058 patie
Eintrag öffnenTrodelvy · 4.8 · Neutropenia occurred in 67.3% of patients treated with sacituzumab govitecan, including Grade 3-4 neutropenia
Eintrag öffnenTrodelvy · 4.8 · Sacituzumab govitecan as monotherapy
Eintrag öffnenTrodelvy · 4.8 · Sacituzumab govitecan in combination with pembrolizumab
Eintrag öffnenTrodelvy · 4.8 · The combination of sacituzumab govitecan with pembrolizumab did not increase the frequency or severity of pemb
Eintrag öffnenTrodelvy · 4.8 · The data below reflect information for significant adverse reactions for sacituzumab govitecan as monotherapy
Eintrag öffnenTrodelvy · 4.8 · The most common adverse reactions reported in patients treated with sacituzumab govitecan were: neutropenia (6
Eintrag öffnenTrodelvy · 4.8 · The most frequently reported serious adverse reactions in patients treated with sacituzumab govitecan were feb
Eintrag öffnenTrodelvy · 4.8 · The safety of sacituzumab govitecan in combination with pembrolizumab has also been evaluated in a clinical st
Eintrag öffnenTrodelvy · 4.8 · When sacituzumab govitecan is administered in combination with pembrolizumab, refer to the SmPC for the respec
Eintrag öffnensacituzumab govitecan
Eintrag öffnensacituzumab govitecan
Eintrag öffnen